pubs.acs.org/joc
which has to be neutralized with an equimolar amount of
Al(OTf)3-Mediated Epoxide Ring-Opening
Reactions: Toward Piperazine-Derived
Physiologically Active Products
base, generating significant amounts of salts in the process
and rendering the separation of water-soluble amino alco-
hols from the salts nontrivial. In organic-soluble amino
alcohols the purification is not particularly onerous, but salt
byproduct are generated nevertheless.
D. Bradley G. Williams* and Adam Cullen
Piperazine-based β-amino alcohols are known for their
biological activity. They find applications as positive ino-
tropic agents, increasing myocardial contractivity, in the
treatment of cardiac disorders such as congestive heart failure.5-8
Examples include Carsatrin5 and DPI201-1066 (1 and 2,
Figure 1). A notable β-amino alcohol is propranolol (3,
Figure 1), one of the first non-selective β-blockers developed
finding widespread use in the treatment of hypertension.
They have also found applications as Ca2þ antagonists4a-d
and dopamine uptake inhibitors.4a-d The quinoline-based
β-amino alcohols similar to 4 bearing the piperazine motif
(Figure 1) have even found application in the reversal of
multidrug resistance in cancer cells.9 Piperazine 4 showed
activity four times higher than Verapamil, a calcium channel
blocking drug that is known to reverse multidrug resistance
in cancerous cells.9
Department of Chemistry, University of Johannesburg, P.O.
Box 524, Auckland Park 2006, South Africa
Received September 22, 2009
In all cases the synthesis included the reaction of a
chlorohydrin with a nucleophile in the presence of stoichio-
metric amounts of base or by the ring opening of an epoxide,
where the epoxide was heated in the presence of the
nucleophile.4a-d,5-9 Obvious advantages of using an epoxide
as a substrate in the generation of 1,2-amino alcohols are the
general atom efficiency of the reaction.
Previous work performed in our laboratories reported the
use of Al(OTf)3 as an efficient Lewis acid catalyst for the ring
opening of epoxides by various alcohols as well as by
aliphatic and aromatic amines (Scheme 1).10 The aminolysis
reaction was found to be regioselective for nucleophilic
attack at the less hindered carbon atom of the epoxide ring,
a feature of SN2-type reaction mechanisms as opposed to a
borderline SN2-type mechanism, which may favor attack at
the more hindered carbon center.10 Catalyst reuse was also
accomplished by simple extraction of the catalyst with water,
once the reaction had been completed, and subsequently
removing the water under reduced pressure and elevated
temperatures. The catalyst was found to retain its activity
through three cycles. Other Lewis acids reported to be active
toward the ring opening of epoxides include Ti(OiPr)4,11
Al(OTf)3 is a good catalyst for the ring opening of ep-
oxides, forming β-amino alcohols bearing the piperazine
motif. Two different strategies were examined, where the
glycidyl ether resided on one-half of the molecule or the
other, allowing insight into a best-case approach for the
ring-opening step. Each half of the molecule contained an
heteroatom that could be used either to attach the glycidyl
moiety or as the nucleophile in the ring-opening reaction,
for the same set of reagents, allowing this approach.
1,2-Amino alcohols represent an important class of organic
molecules. They have found application in medicinal chem-
istry,1 organic synthesis in general, and particularly in asym-
metric synthesis as chiral ligands and auxiliaries.2 These
molecules are usually prepared by reacting an epoxide at
elevated temperatures in the presence of an excess of
an amine.3 Alternatively, a preformed halohydrin can be
reacted with an amine in the presence of a stoichiometric
amount of a base.4a-d The apparent disadvantage of this
method is the generation of undesired hydrohalous acid,
(5) Press, J. B.; Falotico, R.; Hajos, Z. G.; Sawyers, R. A.; Kanojia,
R. M.; Williams, L.; Haertlein, B.; Kauffman, J. A.; Lakas-Weiss, C.; Salata,
J. J. J. Med. Chem. 1992, 35, 4509–4515.
(1) Ager, D. J.; Prakash, I.; Schaad, D. R. Chem. Rev. 1996, 96, 835–875.
(2) Corey, E. J.; Helal, C. J. Angew. Chem., Int. Ed. 1998, 37, 1986–2012.
(3) Deyrup, J. A.; Moyer, C. L. J. Org. Chem. 1969, 34, 175–179.
(4) (a) Kimura, M.; Masuda, T.; Yamada, K.; Mitani, M.; Kubota, N.;
Kawakatsu, N.; Kishii, K.; Inazu, M.; Kiuchi, Y.; Oguchi, K.; Namiki, T.
Bioorg. Med. Chem. 2003, 11, 3953–3963. (b) Kimura, M.; Masuda, T.;
Yamada, K.; Mitani, M.; Kubota, N.; Kawakatsu, N.; Kishii, K.; Inazu, M.;
Kiuchi, Y.; Oguchi, K.; Namiki, T. Bioorg. Med. Chem. 2003, 11, 1621–1630.
(c) Kimura, M.; Masuda, T.; Yamada, K.; Mitani, M.; Kubota, N.;
Kawakatsu, N.; Kishii, K.; Inazu, M.; Kiuchi, Y.; Oguchi, K.; Namiki, T.
Bioorg. Med. Chem. 2004, 12, 3069–3078. (d) Kimura, M.; Masuda, T.;
Yamada, K.; Mitani, M.; Kubota, N.; Kawakatsu, N.; Kishii, K.; Inazu, M.;
Kiuchi, Y.; Oguchi, K.; Namiki, T. Bioorg. Med. Chem. Lett. 2004, 14, 4287–
4290.
(6) Barton, D. L.; Press, J. B.; Hajos, Z. G.; Sawyers, R. A. Tetrahedron:
Asymmetry 1992, 3, 1189–1196.
(7) Butrous, G. S.; Debbas, N. M. G.; Erwin, J.; Davies, D. W.; Keller,
H. P.; Lunnon, M. W.; Nathan, A. W.; Camm, A. J. Eur. Heart J. 1988, 9,
489–497.
(8) Sircar, I.; Haleen, S. J.; Burke, S. E. J. Med. Chem. 1992, 35, 4442–
4449.
(9) Suzuki, T.; Fukazawa, N.; San-nohe, K. J. Med. Chem. 1997, 40,
2047–2052.
(10) (a) Williams, D. B. G.; Lawton, M. Tetrahedron Lett. 2006, 47, 6557–
6560. (b) Williams, D. B. G.; Lawton, M. Org. Biomol. Chem. 2005, 3, 3269–
3272.
(11) Sagawa, S.; Abe, H.; Hase, Y.; Inaba, T. J. Org. Chem. 1999, 64,
4962–4965.
DOI: 10.1021/jo9020437
r
Published on Web 11/16/2009
J. Org. Chem. 2009, 74, 9509–9512 9509
2009 American Chemical Society